Latest oncology insights for medical professionals and patients| Curating the latest in research, trials & treatment advances| Own Views| Not medical advice
Worldwide
- Tweets 2,157
- Following 754
- Followers 1,010
- Likes 1,887
Pinned Tweet
⭐️ Current Role of CAR T-Cell Therapy in #MultipleMyeloma
🎙️ @OncBrothers w/ @CohenAd_MMdoc @kansagraMD @SurbhiSidanaMD
👉 Cilta-cel approved in 2L (CARTITUDE-4: durable PFS + OS benefit)
👉 Sequence CAR T before bispecifics when possible
👉 Optimize holding/bridging & refer early at 1st relapse
#mmsm #CART #HemOnc #OncTwitter #MedEd
🎥 Full discussion +summary👇
oncupdates.com/video-podcast…
1
3
4
687
OncUpdates retweeted
⭐️ New option for maintenance in ES-SCLC | What #DeLLphi-305 means for patients
✍️@sawyer_bawek
🫁 Tarlatamab + durvalumab vs durvalumab alone after chemo-IO induction
✅ mOS: 21.1 vs 12.7 mo (58% ↓ risk of
🔑 Supports a new maintenance standard of care
#LCSM #SCLC #OncTwitter #LungCancer #ESMO26 #MedTwitter
📖 Full patient-focused breakdown 👇
oncupdates.com/article/a-new…
4
2
626
OncUpdates retweeted
Current Role of CAR T-Cell Therapy in #MultipleMyeloma
⭐️ Current Role of CAR T-Cell Therapy in #MultipleMyeloma
🎙️ @OncBrothers w/ @CohenAd_MMdoc @kansagraMD @SurbhiSidanaMD
👉 Cilta-cel approved in 2L (CARTITUDE-4: durable PFS + OS benefit)
👉 Sequence CAR T before bispecifics when possible
👉 Optimize holding/bridging & refer early at 1st relapse
#mmsm #CART #HemOnc #OncTwitter #MedEd
🎥 Full discussion +summary👇
oncupdates.com/video-podcast…
2
3
284
OncUpdates retweeted
🫁Targeting EGFR exon 20 ins #NSCLC | #WCLC26 updates
👉@ElaineShumMD+Dr. Bazhenova discuss sunvozertinib, amivantamab, & zipalertinib data + practical considerations!
#LCSM #EGFR #OncTwitter #LungCancer #MedEd #MedTwitter @nyulangone @UCSDHealth #MedX
oncupdates.com/video-podcast…
2
5
515
OncUpdates retweeted
⭐️ New option for maintenance in ES-SCLC | What #DeLLphi-305 means for patients
📖 Full patient-focused breakdown 👇
oncupdates.com/article/a-new…
#LCSM #SCLC #OncTwitter #LungCancer #Tarlatamab #ESMO26 #MedTwitter #MedX #Oncology @myESMO
⭐️ New option for maintenance in ES-SCLC | What #DeLLphi-305 means for patients
✍️@sawyer_bawek
🫁 Tarlatamab + durvalumab vs durvalumab alone after chemo-IO induction
✅ mOS: 21.1 vs 12.7 mo (58% ↓ risk of
🔑 Supports a new maintenance standard of care
#LCSM #SCLC #OncTwitter #LungCancer #ESMO26 #MedTwitter
📖 Full patient-focused breakdown 👇
oncupdates.com/article/a-new…
3
4
399
OncUpdates retweeted
📣 We need to see the data, but exciting announcement that 🐯 LiGeR-HN1 (petosemtamab [peto] + pembro vs pembro in 1L R/M) has reportedly met its dual 1° endpoints of OS and ORR in HPV- and HPV+ #hnscc #hncancer #hncsm
us.genmab.com/company/news/p…
@OncoAlert @OncBrothers @OncLive @OncUpdates
2
3
379
OncUpdates retweeted
⭐️ Ep. 2 | #ESMO26 #HERIZON-GEA-01: Role of tislelizumab in 1L HER2+ mGEA
🎙️ @KlempnerSam & @ShrutiPatelMD
✅ Triplet mOS 27 mo vs 22.9 mo (doublet)
✅ ~8.3% higher 3-yr OS
✅ Consistent trend across PD-L1 TAP
#GIOnc #HER2 #OncTwitter #gicsm #MedTwitter
🎥 Full discussion 👇
oncupdates.com/video-podcast…
3
2
228
OncUpdates retweeted
🚨Top 10+ Key Studies Presented at #ESMO26 from @OncBrothers
👉Check out this list of studies that are changing/reinforcing current standard of care!
🤔What other studies do you have highlighted on your list?
#OncTwitter #MedTwitter #ESMO #MedX #bcsm #lcsm #gucsm #gicsm
We are all done with #ESMO26! 10+ studies that were on our radar and the updated data around them.
Out in the community settings, it’s tough to keep up with all that is happening here in the world of cancer (and this was just ONE conference). Really appreciate you all sharing the data and importantly your take around this: @OncoAlert @weoncologists @DrChoueiri @StephenVLiu @SuyogCancer @dr_yakupergun @drsarahsam @PTarantinoMD @GIMedOnc @BijoyTelivala @RenoHemonc @nlindenberg @jryckman3 @ErikaHamilton9 @myESMO @LorenzaRimassa 🙏🏽🙏🏽
3
2
271
OncUpdates retweeted
🚨 #ESMO26 | INTerpath-001: Personalized mRNA neoantigen vaccine (intismeran) + pembrolizumab vs placebo + pembrolizumab in resected stage IIB–IV melanoma 💉
✅ 2-yr RFS: 82.2% vs 70.0%
✅ 2-yr DMFS: 88.5% vs 80.2%
⚠️OS immature
#Melanoma #OncTwitter #medX #MedTwitter
1
200
OncUpdates retweeted
#ESMO26: 4 talking points .
1️⃣ A Presidential LBA leaked to the press in full >24 hours before presentation.
2️⃣ 5 of 12 Presidential LBAs featured China-origin molecules. Is oncology’s centre of gravity shifting east? 🇨🇳
3️⃣ The most anticipated trial didn’t get the biggest applause.
4️⃣ Three Presidential Symposia. Zero audience Q&As . @myESMO
See u at next esmo conference - hopefully in person 🙂
6
10
41
6,179
OncUpdates retweeted
So happy to have the @OncBrothers around so I can try to stay on-top of things outside of GI Oncology. Ya'll fill such a critical role for the field.
We are all done with #ESMO26! 10+ studies that were on our radar and the updated data around them.
Out in the community settings, it’s tough to keep up with all that is happening here in the world of cancer (and this was just ONE conference). Really appreciate you all sharing the data and importantly your take around this: @OncoAlert @weoncologists @DrChoueiri @StephenVLiu @SuyogCancer @dr_yakupergun @drsarahsam @PTarantinoMD @GIMedOnc @BijoyTelivala @RenoHemonc @nlindenberg @jryckman3 @ErikaHamilton9 @myESMO @LorenzaRimassa 🙏🏽🙏🏽
1
4
26
1,965
OncUpdates retweeted
⭐️ #ESMO26 | #HERIZON-GEA-01: OS benefit with zanidatamab regimens in 1L HER2+ mGEA
🎙️ @KlempnerSam & @ShrutiPatelMD
✅ mOS: 22.9 vs 19.6 mo (HR 0.76) zani+chemo vs tras+chemo
✅ Triplet mOS: 27 mo
#GIOnc #HER2 #OncTwitter #gism
🎥 Full discussion 👇
oncupdates.com/video-podcast…
4
4
589
OncUpdates retweeted
Day 4 (Presidential III) #ESMO26 highlights:
1. ARTEMIS-011: Risvutatug rezetecan (B7-H3 ADC) in osteosarcoma
2. MOIO: ⬇️ frequency IO in responders
3. TroFuse-005: Sac-TMT in ndometrial Ca
4. KEYNOTE-C93: Pembro mono in 1L dMMR Endometrial Ca
#OncTwitter @myESMO
1/5
2
15
38
3,891
OncUpdates retweeted
For the first time, ADCs deliver a statistically positive truck test in sarcomas! 🛻
Hey @PTarantinoMD ! I guess we can say this passes the truck test?
glad to see #sarcoma at the plenaries both at @ASCO and @myESMO
3
36
215
16,534
OncUpdates retweeted
⭐️Inavolisib data, eligibility & side effects from #INAVO120
🎙️ @KalinskyKevin discusses Inavolisib with @OncBrothers
🎥Watch the full discussion 👇
oncupdates.com/video-podcast…
#OncTwitter #BreastCancer #PIK3CA #Inavolisib #bcsm
2
7
544